Microphthalmia transcription factor

Dorvault, Christine C.; Weilbaecher, Katherine N.; Yee, Herman; Fisher, David E.; Chiriboga, Luis; Xu, Ying; Chhieng, David C.

doi:10.1002/cncr.9049

Cited by 38 publications

(8 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this small number of SLNs, Mitf demonstrates a specificity of 100%. This is comparable to a specificity of 97% as described by Sheffield et al in 72 primary melanomas and 32 nonmelanocytic malignancies [6] and a specificity of 100% as found by Dorvault et al [14]. Miettinen et al suggest caution in the use of Mitf in the search for nodal micrometastasis as they found occasional Mitf-positive nuclei in histiocytes of germinal centers in 8 out of 20 lymph nodes and in sinus histiocytes in 7 out of 22 lymph nodes.…”

Section: Discussionsupporting

confidence: 63%

“…In mice, the allele Mitf mi leads to complete absence of melanocytes in the homozygous state [12]. In contrast to various melanocytic markers, such as melanin or c-kit, whose expression may be lost or difficult to detect in malignant melanocytic lesions, Mitf expression is usually maintained in human melanoma specimens [7,9,10,11,13,14]. Different signaling molecules or transcription factors implicated genetically in melanocyte development are known to either affect Mitf expression or its function [19].…”

Section: Discussionmentioning

confidence: 99%

“…It is important for the survival of melanocytes and regulates the expression of several melanocyte genes. Multiple studies have confirmed that Mitf is a sensitive marker for epitheloid melanomas: 82% to 100% of melanomas are positive for Mitf [6,9,10,11,13,14]. Recently we suggested that Mitf may be a new molecular prognostic marker in melanoma patients with low levels of Mitf expression correlating with worse prognosis [9].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Expression of Microphthalmia Transcription Factor in Sentinel Lymph Nodes of Patients with Melanoma

Hellan¹,

Gentile²,

Ailabouni³

et al. 2011

JCT

View full text Add to dashboard Cite

Background: Sentinel lymph node biopsy is widely used in the management of melanoma patients. Multiple markers are used to stain sentinel lymph node tissue including S100, HMB-45 and melan A with different success. We investigated, for the first time, the use of Microphthalmia transcription factor (Mitf) staining in a larger series of sentinel lymph nodes. Mitf is a transcription factor essential for the development and survival of melanocytes. It has been introduced recently as a sensitive and specific marker for melanomas. Methods: Thirty patients with cutaneous melanoma were included in our study: twenty patients underwent sentinel lymph node biopsy; ten patients underwent complete lymph node dissection for clinically positive disease. Results: Ten out of twenty sentinel lymph nodes were negative for tumor cells and showed no Mitf staining. Out of the ten positive sentinel lymph nodes, eight were also positive for Mitf. Only four out of the ten clinically positive lymph nodes stained for Mitf. Conclusions: We conclude that Mitf can be used as an additional marker for evaluating sentinel lymph nodes in patients with melanoma. In addition, our results imply that Mitf is involved in melanoma differentiation

show abstract

Section: Discussionsupporting

confidence: 63%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Expression of Microphthalmia Transcription Factor in Sentinel Lymph Nodes of Patients with Melanoma

Hellan¹,

Gentile²,

Ailabouni³

et al. 2011

JCT

View full text Add to dashboard Cite

show abstract

“…10 serial 4‐μm sections were also prepared from one cut face of the node by the method described by Cochran et al. , 3 and stained in sequence with HE for S‐100 protein, with HE for HMB‐45, and with HE for Melan‐A 6–13 (Table 2). Immunostaining for S‐100 protein, HMB‐45 and Melan‐A was performed by the avidin‐biotin‐peroxidase complex (ABC) method.…”

Section: Case Reportmentioning

confidence: 99%

Clinicopathological significance of sentinel node biopsy in Japanese patients with cutaneous malignant melanoma

Noro

Yamazaki²,

Nakanishi

et al. 2010

The Journal of Dermatology

View full text Add to dashboard Cite

Sentinel node biopsy (SNB) for malignant melanoma began to be performed in our department in 1997. A total of 121 patients underwent SNB. Sentinel node (SN) were identified in 39 (83.0%) of the 47 cases in which the blue dye method alone was used, and in 71 (95.9%) of the 74 cases by combination of dye, radioisotope, and γ probe methods. The excised SN was cut through its longest meridian, and the cut surfaces were stained with hematoxylin and eosin (HE) and examined for the presence (SN(+) ) or absence (SN(-) ) of melanoma cells. If no melanoma cells were detected, serial sections were prepared and examined by sequential staining with HE, for S-100 protein, with HE, for HMB-45, with HE, and for Melan-A. In this study minute metastasis (SNm(+) ) was defined as tumor cells newly identified in the immunostained section. The thickness of tumors ranged 0-38.0 mm, and their mean thickness was 4.5 mm. There were 39 SN(+) cases (39/110 [39+71]; 35.5%) and seven SNm(+) cases (7/110 [39+71]; 6.4%). The 5-year survival rate was significantly higher in the SN(-) group than in the SN(+) group and SNm(+) group combined (P=0.0002). The survival rate of the SNm(+) group was not significantly different from that of the SN(+) group (P=0.3848). The 5-year survival rate of the SN(+) group and SNm(+) group combined was significantly higher than that of the group with clinically unequivocal metastatic nodes (P=0.0001). Accurate SNB results will provide important prognostic information for Japanese patients with melanoma.

show abstract

“…However, the diagnostic utility of this immunostain is limited by broad expression of its target antigen in other cell types of neural crest origin and its failure to stain up to 7% of melanomas. 1–6 Melan-A (and its closely related antigen MART-1) is a commonly used alternative to S100 because of its perceived high sensitivity and specificity for melanocytes. Recent studies, though, have suggested that Melan-A overestimates the number of melanocytes in solar lentigenes and MIS, and stains keratinocytes in the setting of inflammation.…”

Section: Introductionmentioning

confidence: 99%

MITF Accurately Highlights Epidermal Melanocytes in Atypical Intraepidermal Melanocytic Proliferations

Nybakken¹,

Sargen²,

Abraham³

et al. 2013

The American Journal of Dermatopathology

View full text Add to dashboard Cite

Atypical intraepidermal melanocytic proliferations (AIMP) have random cytologic atypia and other histologic features that are concerning for malignancy and often require immunohistochemistry to differentiate from melanoma in situ. Immunostaining with S100, Melan-A, and MITF was performed for forty-nine morphologically well-characterized AIMP lesions. The percentage of cells in the basal layer of the epidermis that were identified as melanocytes by immunohistochemistry was compared to the percentage observed by morphology on hematoxylin and eosin staining, which is the gold standard stain for identifying cytologic atypia within an AIMP. Melan-A estimated the highest percentage of melanocytes and S100 the fewest in 47 of the 49 lesions examined. The estimated percentage of melanocytes was 23.3% (95% CI: 18.6, 28.1; p<0.001) higher for Melan-A compared to hematoxylin and eosin staining. Melanocyte estimates were similar for H&E and MITF (p=0.15) while S100 estimated 21.8% (95% CI: −27.2, −16.4; p<0.001) fewer melanocytes than H&E. Melan-A staining produces higher estimates of epidermal melanocytes than S100 and MITF, which may increase the likelihood of diagnosing melanoma in situ. In contrast, melanoma in situ may be underdiagnosed with the use of S100, which results in lower estimates of melanocytes than the other two immunostains. Therefore, the best immunohistochemical marker for epidermal melanocytes is MITF.

show abstract

Microphthalmia transcription factor

Cited by 38 publications

References 31 publications

Expression of Microphthalmia Transcription Factor in Sentinel Lymph Nodes of Patients with Melanoma

Expression of Microphthalmia Transcription Factor in Sentinel Lymph Nodes of Patients with Melanoma

Clinicopathological significance of sentinel node biopsy in Japanese patients with cutaneous malignant melanoma

MITF Accurately Highlights Epidermal Melanocytes in Atypical Intraepidermal Melanocytic Proliferations

Contact Info

Product

Resources

About